SUPT7L

Across TCGA pan-cancer cohorts, SUPT7L RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated SUPT7L data layer compared with 5 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SUPT7L RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SUPT7L expression acts as an unfavorable survival marker, although some lineages such as READ and ESCA show a favorable association.

LIHC, ACC, and BLCA are the cancer types where SUPT7L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.601	0.769	<.001	112	view →
ACC	DFS	Median	All	0.207	0.668	<.001	110	view →
BLCA	DFS	Tertile	All	0.229	0.558	<.001	38	view →
MESO	DFS	Median	II,III,IV	0.297	0.603	.011	36	view →
UVM	OS	Median	III,IV	0.296	1.000	.005	35	view →
COAD	OS	Quartile	All	0.707	0.907	.002	32	view →
READ	OS	Median	III,IV	0.863	0.606	.002	31	view →
SKCM	DFS	Tertile	II,III,IV	0.599	0.837	.002	23	view →
UCEC	DFS	Quartile	All	0.548	0.824	.005	22	view →
LGG	DFS	Median	All	0.793	0.869	.004	21	view →
CESC	DFS	Median	All	0.664	0.808	.001	18	view →
ESCA	DFS	Quartile	All	1.000	0.398	.018	17	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

SUPT7L–LIHC (OS)

Open the LIHC breakdown →